NCT07022834View on ClinicalTrials.gov

Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in Children

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

June 1, 2028

Study Completion Date

June 1, 2030

Conditions
Langerhans Cell Histiocytosis (LCH)
Interventions
DRUG

Dabrafenib or Trametinib and Clofarabine

"Drug: Dabrafenib or Trametinib Dabrafenib: 3-5 mg/kg/day; Trametinib: 0.025mg/kg/day~Drug: Clofarabine Consolidation therapy: 25 mg/m2/d, days 1-5 Maintenance therapy: 25 mg/m2/d, days 1-2"

Trial Locations (1)

610041

RECRUITING

Department of Pediatric Hematology and Oncology, West China Second University Hospital, Sichuan University, Chengdu, China, Chengdu

All Listed Sponsors
lead

West China Second University Hospital

OTHER

NCT07022834 - Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in Children | Biotech Hunter | Biotech Hunter